ArticleBiotechnology and bioengineering2021
Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
Article in Biotechnology and bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Comparative production of recombinant capripoxvirus in Vero cells using microcarrier- and macrocarrier-based dynamic cell culture systems under serum-free conditions.Applied microbiology and biotechnology · 2026Article
- Article
- Production of the Bakırköy strain of sheeppox vaccine virus in spinner flasks using an alternative method with Cytodex 1 microcarriers on Vero cells.BMC biotechnology · 2025Article
- Production Optimization, Adjuvant Screening and Immunogenicity Evaluation of a Virus-like Vesicle Rabies Vaccine.Vaccines · 2025Article
- Article
- Perfusion process with tangential flow filtration for oncolytic VSV-GP production.Frontiers in bioengineering and biotechnology · 2025Article
- Development of Long-Term Stability of Enveloped rVSV Viral Vector Expressing SARS-CoV-2 Antigen Using a DOE-Guided Approach.Vaccines · 2024Article
- Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine.Viruses · 2024Article
- Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective.ACS omega · 2024Review
- High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors.Molecular therapy. Methods & clinical development · 2024Article
- Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-CelFrontiers in bioengineering and biotechnology · 2024Article
- Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine.Vaccines · 2023Article
- Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor.Biotechnology reports (Amsterdam, Netherlands) · 2023Article
- Optimization of VSV-ΔG-spike production process with the Ambr15 system for a SARS-COV-2 vaccine.Biotechnology and bioengineering · 2022Article
- Article
- Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects.Frontiers in bioengineering and biotechnology · 2022Review
- Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures.Vaccines · 2021Article
- Large-Scale Microcarrier Culture of Chinese Perch Brain Cell for Viral Vaccine Production in a Stirred Bioreactor.Vaccines · 2021Article
- Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.Biotechnology and bioengineering · 2021Article
- Fed-batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The Vero cell line is the most used continuous cell line in viral vaccine manufacturing. This adherent cell culture platform requires the use of surfaces to support cell growth, typically roller bottles, or microcarriers. We have recently compared the production of rVSV-ZEBOV on Vero cells between microcarrier and fixed-bed bioreactors. However, suspension cultures are considered superior with regard to process scalability. Therefore, we further explore the Vero suspension system for recombinant vesicular stomatitis virus (rVSV)-vectored vaccine production. Previously, this suspension cell line was only able to be cultivated in a proprietary medium. Here, we expand the adaptation and bioreactor cultivation to a serum-free commercial medium. Following small-scale optimization and screening studies, we demonstrate bioreactor productions of highly relevant vaccines and vaccine candidates against Ebola virus disease, HIV, and coronavirus disease 2019 in the Vero suspension system. rVSV-ZEBOV, rVSV-HIV, and rVSV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.